Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293715 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL31378278 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL16293721 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL16294102 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL16293722 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL25405291 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL16294490 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL15500967 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL19995666 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL6297011 | 0.98 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| EP-0248597-A2 | Phospholipase A2 inhibitors and methods of synthesis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | HCAR2 101/4885KEAP1 1268/4885NFE2L2 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.